Tarsus Pharmaceuticals, Inc. — Director's Dealing 2020

Oct 16, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Tarsus Pharmaceuticals, Inc. (TARS)
CIK: 0001819790
Period of Report: 2020-10-15

Reporting Person: Tester Jason E. (Director, 10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Preferred Stock	$		Common Stock (21575)		Indirect
Series B Preferred Stock	$		Common Stock (3698)		Indirect
Series A Preferred Stock	$		Common Stock (1434790)		Indirect
Series B Preferred Stock	$		Common Stock (245966)		Indirect
Series C Preferred Stock	$		Common Stock (71427)		Indirect

Footnotes

F1: The Series A Preferred Stock shall automatically convert into shares of the Issuer's common stock, par value $0.0001 per share (the "Common Stock"), on a one-for-one basis, immediately prior to the closing of the Issuer's initial public offering. The Series A Preferred Stock has no expiration date.

F2: The Reporting Person is the trustee of the Tester Living Trust, and has voting and dispositive power with respect to these shares.

F3: The Series B Preferred Stock shall automatically convert into shares of Common Stock, on a one-for-one basis, immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock has no expiration date.

F4: The shares are held directly by Horowitz Limited Partnership VIII. The Reporting Person is the Chief Financial Officer of Horowitz Management, Inc., the managing partner of Horowitz Limited Partnership VIII. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

F5: The Series C Preferred Stock shall automatically convert into shares of Common Stock, on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series C Preferred Stock has no expiration date.